Product Description
Rare Thyroid Therapeutics International is developing Tiratricol as a treatment for Allan-Herndon-Dudley Syndrome. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT02396459)
Mechanisms of Action: THR Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Topical,Percutaneous,Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Argentina | Brazil | Chile | Colombia | France | Hong Kong | Peru | United Kingdom | Uruguay
Approved Indications: None
Known Adverse Events: None
Company: Rare Thyroid Therapeutics International
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Czech Republic, Netherlands, United Kingdom, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Allan-Herndon-Dudley Syndrome|Mental Retardation, X-Linked|Muscle Hypotonia|Muscular Atrophy
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| MCT8-2019-2 | P2 |
Active, not recruiting |
Allan-Herndon-Dudley Syndrome |
2026-09-07 |
2025-05-02 |
Treatments |
|
| ReTRIACt | P3 |
Recruiting |
Muscular Atrophy|Allan-Herndon-Dudley Syndrome|Muscle Hypotonia|Mental Retardation, X-Linked |
2025-04-01 |
8% |
2024-10-17 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| MCT8-2021-3 | P3 |
Recruiting |
Allan-Herndon-Dudley Syndrome |
2025-02-28 |
2025-05-02 |
Treatments |